Related Experiment Video
Updated: Jun 15, 2026
11:10
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
Structural basis for a PABPN1 aggregation-preventing antibody fragment in OPMD
Antonietta Impagliazzo1, Armand W Tepper, Theo C Verrips
1Leiden University Medical Center, Center for Human and Clinical Genetics, Leiden, The Netherlands. a.impagliazzo@lumc.nl
FEBS Letters
|March 16, 2010
Summary
Oculopharyngeal muscular dystrophy (OPMD) involves PABPN1 protein buildup in muscle. A llama antibody, 3F5, blocks this aggregation, offering potential OPMD therapeutic insights.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Oculopharyngeal muscular dystrophy (OPMD) is a genetic disorder characterized by progressive muscle weakness.
- It stems from alanine expansions in the polyadenylate binding protein nuclear 1 (PABPN1) gene, leading to protein aggregation within skeletal muscle nuclei.
Purpose of the Study:
- To elucidate the structural basis of the interaction between the 3F5 llama antibody and the PABPN1 protein.
- To understand how 3F5 binding interferes with PABPN1 aggregation, a key process in OPMD.
Main Methods:
- Protein structure determination
- Antibody-antigen binding interface mapping
- Structural modeling of the 3F5-PABPN1 complex
Main Results:
- The binding interface between 3F5 and PABPN1 was successfully mapped.
- A structural model revealed that 3F5's complementarity determining regions form a cavity accommodating the PABPN1 alpha-helix domain.
- Key residues involved in PABPN1 aggregation were identified within the binding site.
Conclusions:
- The 3F5 antibody targets critical residues involved in PABPN1 aggregation.
- Understanding this interaction provides insights into OPMD pathogenesis.
- The 3F5 antibody shows therapeutic potential for OPMD by inhibiting PABPN1 aggregation.
